Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NQO2 | P16083 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474377 | 0.84 | NQO2 (0.56) | TDP1NQO2MEN1KMT2AHRH4 | |
| SCHEMBL3602260 | 0.80 | HRH4 (0.56) | NQO2MEN1KMT2AHRH4KDM4E | |
| SCHEMBL6304236 | 0.80 | HRH4 (0.56) | NQO2MEN1KMT2AHRH4KDM4E | |
| SCHEMBL4928239 | 0.79 | ALDH1A1 (0.59) | TDP1NQO2MEN1KMT2AHRH4 | |
| SCHEMBL4928778 | 0.79 | NQO2 (0.50) | TDP1NQO2MEN1KMT2AHRH4 | |
| SCHEMBL17848973 | 0.78 | TDP1 (0.52) | TDP1MEN1KMT2AHRH4TSHR | |
| SCHEMBL12410057 | 0.78 | TDP1 (0.52) | TDP1MEN1KMT2AHRH4KDM4E | |
| SCHEMBL444482 | 0.77 | KDM4E (0.44) | NQO2MEN1KMT2AHRH4KDM4E | |
| SCHEMBL4685260 | 0.77 | NPC1 (0.39) | TDP1KMT2AL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL18796358 | 0.76 | ALDH1A1 (0.56) | TDP1NQO2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20230109662-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2023-01-03 | — | — | US | disclosed |
| CN-113195475-A | Inhibitors of human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200360384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-11-19 | — | — | US | disclosed |
| WO-2014139983-A1 | [1,2,4]TRIAZOLO[4,3-A]QUINOXALINES AS DUAL PDE2/PDE10 INHIBITORS | H. LUNDBECK A/S (DK) | 2014-09-18 | — | — | WO | disclosed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| EP-2342191-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-07-13 | — | — | EP | disclosed |
| WO-2005067932-A1 | (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050148586-A1 | Quinoxalinones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-4623725-A | [1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0107455-B1 | TRIAZOLOQUINOXALINES AS ANTIDEPRESSANTS AND ANTIFATIGUE AGENTS | PFIZER INC. (US) | 1986-07-09 | — | — | EP | disclosed |
| US-4547501-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4495187-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0107455-A1 | Triazoloquinoxalines as antidepressants and antifatigue agents | PFIZER INC. (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | TDP1 1193/4885NQO2 335/4885MEN1 4300/4885 |
| US-20230109662-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | TDP1 1193/4885NQO2 335/4885MEN1 4300/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | TDP1 2834/4885NQO2 740/4885MEN1 2870/4885 |
| US-20200360384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | TDP1 1193/4885NQO2 335/4885MEN1 4300/4885 |
| US-20050148586-A1 | Quinoxalinones | SLC5A2, GPR119, GLS2 | TDP1 4015/4885NQO2 5/4885MEN1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.